NCT00290251 2024-07-15
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
6 trialsNCT04832906 2021-04-06
UA Versus UAE in Treatment of Fibroids
Ain Shams Maternity Hospital
Phase 4 Completed
NCT03342859 2021-01-06
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
Bayer
Phase 1 Terminated
NCT00044876 2019-12-17
Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02465814 2016-11-22
ASTEROID 2
Bayer
Phase 2 Completed
NCT02288130 2016-11-03
MYOMEX
Amsterdam UMC, location VUmc
Phase 4 Unknown